Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cynapsus Therapeutics, a specialty central nervous system pharmaceutical company focused on the treatment of OFF episodes in Parkinson’s disease, is pleased to announce the grant of U.S. Patent No. 9,044,475, an additional patent in its sublingual apomorphine portfolio.
Subscribe to our email newsletter
This patent is solely owned by Cynapsus and granted with claims that provide Cynapsus with protection of pharmaceutical dosage forms that combine apomorphine hydrochloride particles with an organic pH neutralizing agent and a permeation enhancer in a sublingual film. This patent is scheduled to expire in June of 2030 and covers Cynapsus’ Parkinson’s product candidate, APL-130277, and related formulations. APL-130277 is designed to be safe and easily self-administered by patients with Parkinson’s disease.
The issued patent is the third to issue as a U.S. patent from the company’s patent application filings directed to sublingual apomorphine therapies. Cynapsus’ intellectual property position includes other patent applications that seek to further protect additional features of sublingual apomorphine films.
"As one of the original inventors and the CEO of Cynapsus, I am pleased that we have obtained this significant patent issuance. This U.S. patent is part of our broad based patent strategy. It is significant to Cynapsus in that it provides protection for our technology that allows for a clinically meaningful and convenient delivery method of apomorphine, the only drug to be known to rapidly turn patients ON while they are experiencing all types of OFF episodes associated with Parkinson’s disease," said Mr. Anthony Giovinazzo, President and CEO.